Skip to main content

Neuroblastoma News

FDA Approves Iwilfin (eflornithine) as Maintenance Therapy for High-Risk Neuroblastoma

LOUISVILLE, Ky.--(BUSINESS WIRE)--USWM, LLC (US WorldMeds) today announced that the U.S. Food and Drug Administration (FDA) has approved Iwilfin ™ (eflornithine) 192 mg tablets, a groundbreaking oral ...

FDA Approves Danyelza (naxitamab-gqgk) for the Treatment of Neuroblastoma

NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) – Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commerc...

FDA Approves Unituxin (dinutuximab) for Pediatric High-Risk Neuroblastoma

On March 10, 2015, the U. S. Food and Drug Administration approved dinutuximab (Unituxin, United Therapeutics Corporation), in combination with granulocyte-macrophage colony-stimulating factor...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Cancer

Related drug support groups

doxorubicin